Interestingly, the activation of nuclear factor erythroid 2‐related transcription factor (Nrf2) via low‐dose radiotherapy (LDRT) treatment has been proposed to cause a shift from M1 to M2 macrophages and a blockade of NLRP3 inflammasomes (Calabrese et al, 2021) and to be potentially beneficial on the lungs of COVID‐19 patients. The gene discussed is NLRP3; the disease is COVID-19.